MedTrace Logo

LenusPro Safety (LPS) Study in Patients With PH

NCT01979822 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2013-11-08

No results posted yet for this study

Summary

The clinical study aims to investigate the numbers of predefined complications in the first six month after implantation of the implantable LENUS Pro® medications pump for intravenous application of treprostinil sodium in patients with PAH.

The manufacturer is Tricumed GmbH, Germany; exclusive marketing rights: OMT GmbH \& Co KG 78665 Frittlingen, Germany.

Conditions

  • Pulmonary Hypertension

Interventions

OTHER

PH patients with LenusPro pump

Observation/measurement of complications in PH patients with LenusPro pump in the frist six month after implantation of pump

Sponsors & Collaborators

  • University Medicine Greifswald

    lead OTHER

Principal Investigators

  • Ralf Ewert, M.D. · University Hospital of Greifswald

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-04-30
Completion
2015-09-30

Countries

  • Austria
  • Germany
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01979822 on ClinicalTrials.gov